Inflation Reduction Act aims to reduce  Medicare insulin expenses.

By The Exchange Team

The newly approved Inflation Reduction Act caps Medicare insulin at $35 per month.

New research from Yale University crushed hopes to lower insulin pricing for 7.9 million diabetes patients.

14% of U.S. insulin users have "catastrophic" spending levels, according to Yale.

Insulin costs at least 40% of their wages once standard housing and food costs are deducted.

The Senate bill has received praise from senior advocacy groups such as AARP.

Medicare can negotiate drug prices. Medicare Part D out-of-pocket spending would be capped at $2,000.

The $2,000 yearly cap for Medicare users is "by far the most important," says RAND senior health economist Andrew Mulcahy.